Rapid quantitative screening of bispecific antibodies using Protein A and HIS1K biosensors
Recent advances in biotechnology have fuelled the development of bispecific antibodies. However, there still remains a number of development challenges for those working in bioprocessing or cell line screening. Many traditional technologies for characterizing antibodies are limited in their ability to provide quantitative functional assessment of two interactions to one bispecific molecule, and commonly used assay platforms like ELISA and SPR are time-intensive.
Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system. They can now identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput on the Octet system was achieved through rapid assay times - binding optimization in only 10 minutes - and through the ability to simultaneously run up to 96 samples.
BLI-based systems are microfluidics-free, which significantly reduces the complexity of the assays. This further eliminates time-consuming cleaning steps and reduces operating costs.
Benefits of BLI technology:
- Label-free, real-time results for kinetic characterization and quantitation of binding interactions
- High quality data even from crude samples, such as cell lysates or culture supernatants
- Automated, high-throughput capacity, measuring up to 96 samples in parallel
- Low maintenance due to microfluidics-free assay format
- Non-destructive measurement allows for reuse of precious sample
Read our application note to learn how you can minimize time, effort, and cost when screening bispecific candidates.
